December 2024 Supplement - Endovascular Today
News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.
Endovascular Today
The 2024 PAD Guideline Update: How It Affects Practice. The most significant changes from the previous guidelines, achieving buy-in and consensus, key trends, obstacles to achieving …
December 2024 Supplement - Endovascular Today
Endovascular Today (ISSN 1551-1944 print and ISSN 2689-792X online) is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, …
Thoracic Aortic Aneurysms: At What Size Should We Intervene?
Thoracic aortic aneurysm (TAA) is a potentially life-threatening disorder that without intervention carries a poor prognosis. Once diagnosed, the 3-year survival for large degenerative TAAs (> …
Merit Medical’s Wrapsody Receives FDA Approval
December 20, 2024—Merit Medical Systems, Inc. announced that the Wrapsody cell-impermeable endoprosthesis has received premarket approval from the FDA.
Iliac Vein Stenting: Best Practices for Patient Safety and Successful ...
Appropriate confirmatory diagnostic imaging on an “intent-to-treat” basis prior to stenting is critical. A combination of multiplanar venography and intravascular ultrasound (IVUS) are gold …
Gore’s Excluder TAMBE Approved by FDA to Treat Complex Aortic …
January 25, 2024—Gore & Associates announced FDA approval for the Excluder thoracoabdominal branch endoprosthesis (TAMBE). The device is an off-the-shelf …
January 2025 Issue - Endovascular Today
Deep Venous Disease Patient Advocacy. Moderator Suresh Vedantham, MD, asks Leslie Lake, Volunteer President of the National Blood Clot Alliance and bilateral PE survivor, about patient …
Prostate Artery Embolization Shown to be Effective as a Long …
March 1, 2023—The Society of Interventional Radiology (SIR) announced findings from a new study that demonstrated that prostate artery embolization (PAE) provides long-term …
Xeltis Receives FDA Breakthrough Device Designation for aXess …
November 19, 2024—Xeltis recently announced that the FDA has granted Breakthrough Device designation for the company’s aXess vascular access conduit and that the first patient was …